IN2014MN02467A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02467A
IN2014MN02467A IN2467MUN2014A IN2014MN02467A IN 2014MN02467 A IN2014MN02467 A IN 2014MN02467A IN 2467MUN2014 A IN2467MUN2014 A IN 2467MUN2014A IN 2014MN02467 A IN2014MN02467 A IN 2014MN02467A
Authority
IN
India
Prior art keywords
tetrahydrothieno
thiazol
dioxo
pyrimidin
difluoro
Prior art date
Application number
Inventor
Suresh Mahadev Kadam
Abraham Thomas
Sukumar Sinha
Sukeerthi Kumar
Bipin Parsottam Kansagra
Sachin Gavhane
Sandeep Bandu Khandagale
Shailesh Pawase
Jayant Prakashrao Patil
Shailendra Bhadane
Bhavna Mishra
Rajesh Dwivedi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Priority to IN2467MUN2014 priority Critical patent/IN2014MN02467A/en
Publication of IN2014MN02467A publication Critical patent/IN2014MN02467A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present disclosure is directed to salts of N {4 [2 4 difluoro 3 (trifluoromethyl)phenyl] 1 3 thiazol 2 yl} 2 (1 3 dimethyl 2 4 dioxo 1 2 3 4 tetrahydrothieno[2 3 d]pyrimidin 5 yl)acetamide and process for the preparation thereof (formula II).
IN2467MUN2014 2012-06-08 2013-06-08 IN2014MN02467A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2467MUN2014 IN2014MN02467A (en) 2012-06-08 2013-06-08

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1687MU2012 2012-06-08
US201261665282P 2012-06-27 2012-06-27
IN3519MU2012 2012-12-13
US201261748016P 2012-12-31 2012-12-31
PCT/IB2013/054703 WO2013183035A2 (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts
IN2467MUN2014 IN2014MN02467A (en) 2012-06-08 2013-06-08

Publications (1)

Publication Number Publication Date
IN2014MN02467A true IN2014MN02467A (en) 2015-07-10

Family

ID=54193746

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2467MUN2014 IN2014MN02467A (en) 2012-06-08 2013-06-08

Country Status (22)

Country Link
US (1) US9458173B2 (en)
EP (1) EP2858999B1 (en)
JP (1) JP5989900B2 (en)
KR (1) KR20150015488A (en)
CN (1) CN104350058A (en)
AP (1) AP3546A (en)
AU (1) AU2013273118B2 (en)
BR (1) BR112014029155A2 (en)
CA (1) CA2873570C (en)
CL (1) CL2014003317A1 (en)
EA (1) EA031334B1 (en)
HK (1) HK1207643A1 (en)
IL (1) IL236084A0 (en)
IN (1) IN2014MN02467A (en)
MX (1) MX354014B (en)
MY (1) MY165622A (en)
NZ (1) NZ701721A (en)
PE (1) PE20142306A1 (en)
PH (1) PH12014502685B1 (en)
SG (1) SG11201408093PA (en)
WO (1) WO2013183035A2 (en)
ZA (1) ZA201500082B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
CA2912578A1 (en) * 2013-06-20 2014-12-24 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
TW202321229A (en) 2021-08-18 2023-06-01 美商富曼西公司 Fungicidal substituted heterocycles
CN114671875A (en) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 Novel dihydropyrimidine compound, isomer or salt, and preparation method and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (en) 1972-10-02 1974-04-11 Basf Ag 3-AMINOISOTHIAZOLO SQUARE BRACKET ON 3.4 SQUARE BRACKET FOR PYRIMIDINE
SE9701398D0 (en) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (en) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 6-PHENYLDIHYDROPIRROLPIRIMIDINDIONA.
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp Pth agonists
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
EP1847541A4 (en) 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND APPLICATIONS THEREOF
AU2006278592A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
TW201900217A (en) 2005-12-22 2019-01-01 美商海卓勒生物科學公司 Compound for regulating TRPA1 function
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CN101454318A (en) * 2006-03-22 2009-06-10 阿斯利康(瑞典)有限公司 Pyridopyrimidine derivatives and their use as pde4 inhibitors
JP2011201776A (en) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd Heterocyclidene-n-(3,4-dihydro-2(1h)-quinazolinon-5-yl)acetamide derivative
CL2008000252A1 (en) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc COMPOUNDS DERIVED FROM QUINAZOLINONA OR PIRIMIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT DISEASES MEDIATED BY CALCIUM CHANNELS, SUCH AS PAIN, DEPRESSION, CARDIOVASCULAR DISEASES, RESPIR
SI3184527T1 (en) 2007-06-22 2020-03-31 Eli Lilly And Company 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
EP2411395B1 (en) * 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
DK2411397T3 (en) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazole-pyrimidinedione derivatives as modulators of TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
BRPI1013559A2 (en) 2009-03-23 2016-04-12 Glenmark Pharmaceuticals Sa compounds, pharmaceutical composition, method of treating disease or condition associated with trpa1 function and their uses
AR084294A1 (en) 2010-12-20 2013-05-08 Glenmark Pharmaceuticals Sa 2-AMINO-4-ARILTIAZOL COMPOUNDS, METHODS FOR SYNTHESIS AND USE AS AN ANTIGONIST OF TRPA1

Also Published As

Publication number Publication date
KR20150015488A (en) 2015-02-10
MY165622A (en) 2018-04-18
PE20142306A1 (en) 2015-01-16
SG11201408093PA (en) 2015-01-29
HK1207643A1 (en) 2016-02-05
AP3546A (en) 2016-01-14
BR112014029155A2 (en) 2017-06-27
JP5989900B2 (en) 2016-09-07
MX354014B (en) 2018-02-08
AU2013273118B2 (en) 2015-11-05
WO2013183035A2 (en) 2013-12-12
IL236084A0 (en) 2015-02-01
CN104350058A (en) 2015-02-11
MX2014014482A (en) 2015-06-05
US20150111038A1 (en) 2015-04-23
CA2873570A1 (en) 2013-12-12
WO2013183035A3 (en) 2014-02-27
EA201492054A1 (en) 2016-08-31
AU2013273118A1 (en) 2014-11-27
PH12014502685A1 (en) 2015-01-26
ZA201500082B (en) 2015-12-23
PH12014502685B1 (en) 2015-01-26
NZ701721A (en) 2016-03-31
JP2015520183A (en) 2015-07-16
CA2873570C (en) 2016-11-01
CL2014003317A1 (en) 2015-02-13
EP2858999A2 (en) 2015-04-15
EP2858999B1 (en) 2017-05-10
AP2014008076A0 (en) 2014-11-30
US9458173B2 (en) 2016-10-04
EA031334B1 (en) 2018-12-28

Similar Documents

Publication Publication Date Title
IN2014MN02467A (en)
PH12015501328A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
PH12015501649A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CO6831982A2 (en) Pyrazolo [4,3-d] pyrimidines useful as kinase inhibitors
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
PH12016500250A1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
EP2788000A4 (en) PYRROLOPYRIMIDINES AS INHIBITORS OF KINASE JANUS
ZA201306719B (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
MY171831A (en) Novel fused pyrimidine compound or salt thereof
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
MX2013015308A (en) Proteasome inhibitors and processes for their preparation, purification and use.
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ701933A (en) Phenoxyethyl piperidine compounds
EA201591105A1 (en) PYRIMIDO [4,5-b] QUINOLIN-4,5- (3H, 10H) -DIONES AS SUPRESSORS NONSENS MUTATIONS
MX2013015436A (en) Amido-pyridyl ether compounds and compositions and their use against parasites.
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX2014010423A (en) Immunologically useful arginine salts.
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
EP2759529A4 (en) PROCESS FOR PREPARING 1-PALMITOYL-3-ACETYLGLYCEROL AND PROCESS FOR PREPARING 1-PALMITOYL-2-LINOLEYL-3-ACETYLGLYCEROL USING THE SAME
EP2702044A4 (en) PROCESS FOR THE PREPARATION OF RILPIVIRINE
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
CR20140545A (en) PIPERAZINO [1,2-A] INDOL-1-ONAS AND [1,4] DIAZEPINO [1,2-A] INDOL-1-ONA
MY164134A (en) Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
MX358151B (en) Sitaxsentan derivative.